Treatment Deintensification Is Uncommon in Adults With Type 2 Diabetes Mellitus: A Retrospective Cohort Study

The Discussion reports that glycemic therapy was rarely reduced even in frail patients or those with multiple comorbidities, and describes harms of intensive glucose control. This supports a rationale for glucose-treatment deintensification, but the paper measures deintensification rates rather than the safety or efficacy of deintensification protocols. It does not study blood-pressure deintensification; that topic appears in a cited reference. The palliative-care relevance is the citing authors’ own conclusion. (LLM, conf=0.84)

The Discussion (page not provided) identifies intensive glycemic control as a potential overtreatment concern for frail patients and those with multiple comorbidities, but cautions that intensive control does not necessarily constitute overtreatment in every case. The patient-characteristics table records insulin and sulfonylurea use, but the paper does not specifically identify treatment plans containing those drugs as overtreatment. (LLM, conf=0.86)

The Discussion reports that intensive glucose control carries risks, especially for older or frail patients, and argues for greater attention to deintensification. But this study measures how often glycemic medications were reduced; it does not establish the safety or efficacy of deintensification protocols, and it does not study blood-pressure deintensification. The palliative-care relevance is the citing authors’ own framing. (LLM, conf=0.79)

The Discussion (page not available) reports that more than three quarters of frail patients or those with multiple comorbidities and HbA1C below 6.5% did not have their diabetes medications reduced, supporting the concern about persistent potentially excessive treatment. The patient-characteristics table lists insulin and sulfonylurea use, but does not establish that intensive regimens including those drugs are very common specifically among older adults with complex conditions; the cohort’s mean age was 53.9 years. (LLM, conf=0.86)

The Discussion reports that more than three quarters of frail patients or those with multiple comorbidities and HbA1C below 6.5% had no reduction in diabetes medication, and it links overtreatment to increased hypoglycemia risk. The WHAT IS KNOWN section also identifies elderly patients and those with comorbidities as especially vulnerable. However, the paper does not specifically identify insulin and/or sulfonylurea regimens in older adults with complex health status as the common overtreatment described; its cohort had a mean age of about 54 (patient-characteristics table). (LLM, conf=0.85)

The Discussion reports that intensive glucose control can cause harm, including hypoglycemia, and argues for greater attention to deintensifying glycemic therapy in frail patients. But this study measured how often therapy was reduced, not the safety or efficacy of deintensification protocols; it did not evaluate blood-pressure deintensification. The copy provides section labels but no page numbers. (LLM, conf=0.82)